Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

Martinsucks2point0 Apr. 25 at 10:31 AM

$SRPT why do people here keep regurgitating the deaths, the kids were very sick and their livers could not handle elevidys. 1100 + kids have taken elevidys and are fine, add on worldwide sales to that number. So 1% of elevidys population ( they were extremely over weight and very ill from other health complications ) my god you people are fucking scum. I hope you will be looking up at us, soon.

0 · Reply

Yatish82 Apr. 25 at 9:39 AM

$SRPT new Def14a. For board meeting and new vote for selection

0 · Reply

maxmemax Apr. 25 at 8:23 AM

$SRPT From the annual report: 1) About SRP-9003 In December 2025, the FDA confirmed that we remain on clinical hold and informed us that it requires data from the study of sirolimus as an immunosuppressant before accepting a biologic license application (“BLA”) for SRP-9003.We anticipate re-engaging with the agency on next steps for the program after we receive data from Cohort 8 of Study 9001-103.

1 · Reply

gazza75799 Apr. 25 at 2:13 AM

$SRPT there is a reason why this is at 20$ for so long. And there are better pastures $VICR

0 · Reply

s3q Apr. 25 at 1:49 AM

$SRPT you know the worse part is all the opportunities missed waiting on this to move up and how many times @Martinsucks2point0 has changed identities. If we got $1 for every new identity he has stock would be close to $85

0 · Reply

s3q Apr. 25 at 1:46 AM

$SRPT we don’t want “imagine “ or “probably “ we want cash $60 now

0 · Reply

s3q Apr. 25 at 1:38 AM

$SRPT $20.01

0 · Reply

s3q Apr. 25 at 1:36 AM

$SRPT here we go again with PMOs. I was just about to say me and Fred are ready for another post on pmos

0 · Reply

Thaigrlsrk Apr. 25 at 1:08 AM

$SRPT Context for the PMO's: Imagine a fatal childhood cancer drug with proven added longivity of 7 years. Think FDA would take it off the market? DMD is 100% fatal, PMO's have shown 5-7 years longivity over Steroids alone. PMO's are 900 million a year in revenue.

0 · Reply

Dkll303 Apr. 25 at 1:02 AM

$SRPT way back , I owned this at $28….got out at $105..in 2017 ..I felt ahaead of itself then .doug came as ceo in july 2017, I was vacationing in France . He put 2M of his own money in at $44, and started his gig. Within 1 year of that July he vowed not to sell the company for less than $185. He had his chance . Since 2018 , lots of ups and downs , which I played with more successes , he now he wants out ( having never selling his Orange County home ) it was always a take out . How it plays out now, is anyone’s guess . All stated is true, for the losers sitting with TAK at $CADL and the misfits running a welfare office for themselves at $AGIO .read it and weep , you pathetic fools

2 · Reply

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Mar 31, 2026, 4:05 PM EDT - 24 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2026, 11:17 AM EDT - 4 weeks ago

Why Is Sarepta Therapeutics Stock Exploding Today?

Mar 25, 2026, 8:05 AM EDT - 4 weeks ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 4 weeks ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 19, 2026, 11:51 AM EDT - 5 weeks ago

Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs

Mar 19, 2026, 8:30 AM EDT - 5 weeks ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 5 weeks ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Feb 27, 2026, 9:00 AM EST - 2 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:52 AM EST - 2 months ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Feb 26, 2026, 5:05 AM EST - 2 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 4:05 PM EST - 2 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 2 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 8:53 AM EST - 3 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:10 AM EST - 3 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 3 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 3 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 12, 2026, 11:58 AM EST - 3 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 3 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 4 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 12:07 PM EST - 5 months ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 8:57 AM EST - 5 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 5 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 5:48 PM EST - 5 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 2:54 PM EST - 5 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 5 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 12:33 PM EST - 6 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:11 PM EST - 6 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 9:55 AM EST - 6 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 6 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 4:27 AM EST - 6 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 6 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:24 PM EST - 6 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 6 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 6 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 6 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 8, 2025, 11:19 AM EDT - 7 months ago

What's Going On Sarepta Stock On Wednesday?

Oct 3, 2025, 8:30 AM EDT - 7 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 8 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 25, 2025, 3:11 AM EDT - 8 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Martinsucks2point0 Apr. 25 at 10:31 AM

0 · Reply

Yatish82 Apr. 25 at 9:39 AM

$SRPT new Def14a. For board meeting and new vote for selection

0 · Reply

maxmemax Apr. 25 at 8:23 AM

1 · Reply

gazza75799 Apr. 25 at 2:13 AM

$SRPT there is a reason why this is at 20$ for so long. And there are better pastures $VICR

0 · Reply

s3q Apr. 25 at 1:49 AM

0 · Reply

s3q Apr. 25 at 1:46 AM

$SRPT we don’t want “imagine “ or “probably “ we want cash $60 now

0 · Reply

s3q Apr. 25 at 1:38 AM

$SRPT $20.01

0 · Reply

s3q Apr. 25 at 1:36 AM

$SRPT here we go again with PMOs. I was just about to say me and Fred are ready for another post on pmos

0 · Reply

Thaigrlsrk Apr. 25 at 1:08 AM

0 · Reply

Dkll303 Apr. 25 at 1:02 AM

2 · Reply

Moemazon Apr. 24 at 11:47 PM

$SRPT 25.01 by end of year?

2 · Reply

hegdaom Apr. 24 at 10:11 PM

$CAPR Deal check — Comparable Deal Check • Sanofi paid ~6x peak sales for Blueprint Medicines ($9.5B deal) • J&J paid ~5x for Intra-Cellular Therapies ($14.6B) • Rare disease deals historically average 4–6x peak revenue CAPR’s profile is arguably stronger than many of these comparables on a per-indication basis given the unmet need in DMD. $SRPT $XBI $IDYA

1 · Reply

hegdaom Apr. 24 at 10:03 PM

$CAPR Buy more boys. Still very cheap at these levels. The Realistic Buyout Range Combining the math with comps, a well-negotiated acquisition at peak sales of $2–2.5B would most likely land in the $150–$250 per share range — with a competitive bidding war potentially pushing it toward the higher end. $XBI $SRPT

1 · Reply

Cote0924 Apr. 24 at 9:42 PM

$CAPR Also closed with the same mkt cap as $SRPT at 2.04B

2 · Reply

Gladiator007 Apr. 24 at 8:12 PM

$NTLA $SRPT I have been holding all my shares over six months without trading

2 · Reply

Initiator1 Apr. 24 at 8:04 PM

$SRPT To explain the manipulation Stock hasn’t traded above its closing price on the day the DM1 and FSHD results were released—not even once—since that announcement.

1 · Reply

free2dream Apr. 24 at 7:59 PM

$SRPT $POET watch the fxck out. POET maket full $1M annual revenue, Sarepta only $1B . therefore poet should have higher valuation of $2.3B vs Sareptsa $2B. trump says $1M is more than $1B so it must be true, right my MAGA MAGGOTS ?$INTC will cure DMD I heard

1 · Reply

Initiator1 Apr. 24 at 7:50 PM

$SRPT Sad when the bulls start giving up. The stranglehold on this stock is criminal to say the least. It feels like the longs have been hit by a freight train. Don’t know if Barry or Doug have made some powerful enemies or it’s something else. But it’s a real test of patience.

0 · Reply

Find_the_Cure Apr. 24 at 7:49 PM

$SRPT options …. heading to $20.00 but don’t know if that’s the maximum pain price. Sad.

0 · Reply

free2dream Apr. 24 at 7:45 PM

$SRPT I am telling you just fxck the kids. They deserve to die. Investors don't give a shit. HC WEIN said so, must be true

1 · Reply

Bonkersfor_chips Apr. 24 at 7:26 PM

$SRPT not even 1 green penny close. Man their earnings better be pretty good. Getting tired of waiting.

1 · Reply

free2dream Apr. 24 at 7:24 PM

$SRPT fxck the kids, let them die. $INTC will cure dmd

1 · Reply

Market Cap	2.14B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	7.13
Profit Margin	-32.45%
Debt to Equity Ratio	0.73

Volume	2,076,500
Avg Vol	2,862,098
Day's Range	N/A - N/A
Shares Out	104.99M
Stochastic %K	47%
Beta	0.29
Analysts	Sell
Price Target	$21.78